Diagnostic and Prognostic Value of Combination Biomarkers in the Critically Ill Patient With Sepsis.

The recruitment status of this study is unknown because the information has not been verified recently.
Verified August 2012 by Southeast University, China.
Recruitment status was  Recruiting
Sponsor:
Collaborator:
Southeast University, China
Information provided by (Responsible Party):
Jianfeng Xie, Southeast University, China
ClinicalTrials.gov Identifier:
NCT01687010
First received: September 13, 2012
Last updated: September 17, 2012
Last verified: August 2012
  Purpose

Sepsis is a common cause for morbidity and mortality in critically ill patients. With the development of medical skills, the mortality is still remain very high. Inappropriateness of initial antibiotic treatment is an important risk factor for mortality and effective antimicrobial administration within the first hour of documented hypotension was associated with increased survival to hospital discharge in adult patients with septic shock. However, the early treatment based on early diagnosis.But it is very difficult to diagnosis because of lack of specific clinic symptom and sign.When severe sepsis occur, biomarker could be helpful to diagnosis. Unfortunately, the diagnostic value of single biomarker is limited. Therefore, combine several biomarkers could enhance the diagnostic value.


Condition
Diagnostic and Predictive Value

Study Type: Observational
Study Design: Time Perspective: Prospective

Resource links provided by NLM:


Further study details as provided by Southeast University, China:

Estimated Enrollment: 300
Study Start Date: March 2012
Estimated Study Completion Date: October 2012
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Critically ill patients

Criteria

Inclusion Criteria:

  • Critically ill patients admitted into ICU

Exclusion Criteria:

  • Age younger than 18 years
  • Refuse to participate in this study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01687010

Contacts
Contact: Jianfeng Xie, M.D. +8602583272201 seuicu@yahoo.com.cn

Locations
China, Jiangsu
Department of Critical Care Medicine Nanjing Zhong-da Hospital Southeast University School of Medicine Recruiting
Nanjing, Jiangsu, China, 210009
Contact: Yi Yang, M.D., Ph.D,    +8602583272202    yiyiyang2004@yahoo.com.cn   
Sponsors and Collaborators
Jianfeng Xie
Southeast University, China
  More Information

No publications provided

Responsible Party: Jianfeng Xie, Physician of critical care department, Southeast University, China
ClinicalTrials.gov Identifier: NCT01687010     History of Changes
Other Study ID Numbers: PCT001
Study First Received: September 13, 2012
Last Updated: September 17, 2012
Health Authority: Food and Drug Administration:China

Keywords provided by Southeast University, China:
CRP, PCT, IL-6, Diagnosis, Prediction

ClinicalTrials.gov processed this record on August 26, 2014